SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Monier R.) srt2:(2015-2019)"

Search: WFRF:(Monier R.) > (2015-2019)

  • Result 1-8 of 8
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Overview of the JET results
  • 2015
  • In: Nuclear Fusion. - : IOP Publishing. - 0029-5515 .- 1741-4326. ; 55:10
  • Journal article (peer-reviewed)
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  • Ruilope, LM, et al. (author)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Journal article (peer-reviewed)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
8.
  • Lerche, E., et al. (author)
  • Optimization of ICRH for core impurity control in JET-ILW
  • 2016
  • In: Nuclear Fusion. - JET, Culham Sci Ctr, EUROfus Consortium, Abingdon OX14 3DB, Oxon, England. [Lerche, E.; Van Eester, D.; Crombe, K.; Kazakov, Y.; Krivska, A.; Ongena, J.] TEC Partner, Assoc EUROFUS Belgian State, LPP ERM KMS, Brussels, Belgium. [Lerche, E.; Jacquet, P.; Giroud, C.; Monakhov, I.; Casson, F. J.; Rimini, F.; Blackman, T.; Brix, M.; Challis, C.; Graham, M.; Kiptily, V.; Lennholm, M.; Lomas, P.; Maggi, C.; Mathews, G.; Mayoral, M. -L.; Santala, M.; Shaw, A.; Stamp, M.] Euratom CCFE Fus Assoc, Culham Sci Ctr, Abingdon, Oxon, England. [Goniche, M.; Colas, L.; Fedorczak, N.; Joffrin, E.; Monier-Garbet, P.] Assoc EUROFUS CEA, IRFM, St Paul Les Durance, France. [Bobkov, V.; Angioni, C.; Hobirk, J.; Puetterich, T.; Reich, M.] EUROFUS Assoziat, Max Planck Inst Plasmaphys, Garching, Germany. [Baruzzo, M.] EUROFUS ENEA Assoc, Consorzio RFX, Padua, Italy. [Brezinsek, S.] TEC Partner, EUROFUS Assoziat, Forschungszentrum Juelich, Julich, Germany. [Czarnecka, A.] EUROFUS Assoc, IPPLM, Warsaw, Poland. [Eriksson, J.] Uppsala Univ, Dept Phys & Astron, Assoc EUROFUS VR, Uppsala, Sweden. [Graves, J. P.] Assoc EUROFUS Confederat Suisse, CRPP EPFL, Lausanne, Switzerland. [Gorini, G.; Mantica, P.; Nocente, M.; Tardocchi, M.; Valisa, M.] EUROFUS ENEA CNR Assoc, Inst Fis Plasma, Milan, Italy. [Johnson, T.] KTH, EES, Fus Plasma Phys, Assoc EUROFUS VR, Stockholm, Sweden. [Meneses, L.; Nave, M. F.; Nunes, I.] EUROFUS IST Assoc, Inst Plasmas & Fusao Nucl, Lisbon, Portugal. [Mlynar, J.; Petrzilka, V.] EUROFUS IPP CR Assoc, Inst Plasma Phys, Prague, Czech Republic. [Petravich, G.] EUROFUS Assoc, MTA Wigner FK RMI, Budapest, Hungary. [Solano, E. R.] EUROFUS Assoc, LNF CIEMAT, Madrid, Spain. [Solano, E. R.] Culham Sci Ctr, EUROfus PMU, Abingdon OX14 3DB, Oxon, England. [Sips, G.] Culham Sci Ctr, JET Exploitat Unit, Abingdon OX14 3DB, Oxon, England. [Tsalas, M.] EUROFUS Assoc, FOM Inst DIFFER, Nieuwegein, Netherlands. : Institute of Physics (IOP). - 0029-5515 .- 1741-4326. ; 56:3
  • Journal article (peer-reviewed)abstract
    • Ion cyclotron resonance frequency (ICRF) heating has been an essential component in the development of high power H-mode scenarios in the Jet European Torus ITER-like wall (JET-ILW). The ICRF performance was improved by enhancing the antenna-plasma coupling with dedicated main chamber gas injection, including the preliminary minimization of RF-induced plasma-wall interactions, while the RF heating scenarios where optimized for core impurity screening in terms of the ion cyclotron resonance position and the minority hydrogen concentration. The impact of ICRF heating on core impurity content in a variety of 2.5 MA JET-ILW H-mode plasmas will be presented, and the steps that were taken for optimizing ICRF heating in these experiments will be reviewed.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-8 of 8

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view